US Stock MarketDetailed Quotes

BCRX BioCryst Pharmaceuticals

Watchlist
  • 8.430
  • +0.420+5.24%
Close Nov 1 16:00 ET
  • 8.500
  • +0.070+0.83%
Post 19:34 ET
1.74BMarket Cap-11547P/E (TTM)

BioCryst Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

BioCryst Pharmaceuticals Q3 2024 Estimates Date

Currency：USDNov 4, 2024

Estimate YoY
Revenue
114.00M
+31.42%
EPS
-0.06
+67.25%
Analyst Rating
Strong Buy

Nov 3, 2024

BioCryst Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 8 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 120.125M--
Nov 4, 20242024/Q3-- / 113.999M--
Aug 5, 20242024/Q2109.332M / 98.324M--
May 6, 20242024/Q192.761M / 85.505M--
Feb 26, 20242023/Q493.401M / 89.995M--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 120.125M--
Nov 4, 20242024/Q3-- / 113.999M--
Aug 5, 20242024/Q2109.332M / 98.324M--
May 6, 20242024/Q192.761M / 85.505M--
Feb 26, 20242023/Q493.401M / 89.995M--

Unlock Free Earnings Estimates

BioCryst Pharmaceuticals Earnings Reports

  • BioCryst Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 6 16:09 ET

  • BioCryst Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

    May 7 16:07 ET

  • BioCryst Pharmaceuticals | 10-K: FY2023 Annual Report

    Feb 27 16:16 ET

  • BioCryst Pharmaceuticals | 10-Q: Q3 2023 Earnings Report

    Nov 8, 2023 16:12 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 3, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data